Patents by Inventor Matthew Ernst Voss

Matthew Ernst Voss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8859776
    Abstract: The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: October 14, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. Bogen, Yao Ma, Yaolin Wang, Brian Robert Lahue, Latha G. Nair, Manami Shizuka, Matthew Ernst Voss, Margarita Kirova-Snover, Weidong Pan, Yuan Tian, Bheemashankar A. Kulkarni, Craig R. Gibeau, Yuan Liu, Giovanna Scapin, Diane Rindgen, Ronald J. Doll, Timothy J. Guzi, Danny J. Hicklin, Amin Nomeir, Gerald W. Shipps, Jr., Malcolm MacCoss
  • Publication number: 20120208844
    Abstract: The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.
    Type: Application
    Filed: October 5, 2010
    Publication date: August 16, 2012
    Inventors: Stephane L. Bogen, Yao Ma, Yaolin Wang, Brian Robert Lahue, Latha G. Nair, Manami Shizuka, Matthew Ernst Voss, Margarita Kirova-Snover, Weidong Pan, Yuan Tian, Bheemashankar A. Kulkarni, Craig R. Gibeau, Yuan Liu, Giovanna Scapin, Diane Rindgen, Ronald J. Doll, Timothy J. Guzi, Danny J. Hicklin, Amin Nomeir, Cynthia Seidel-Dugan, Gerald W. Shipps, JR., Malcolm MacCoss
  • Patent number: 7884107
    Abstract: In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: February 8, 2011
    Assignee: Merck
    Inventors: Yao Ma, Brian Robert Lahue, Gerald W. Shipps, Jr., Yaolin Wang, Stephane L. Bogen, Matthew Ernst Voss, Latha G. Nair, Yuan Tian, Ronald J. Doll, Zhuyan Guo, Corey O. Strickland, Rumin Zhang, Mark A. McCoy, Weidong Pan, Elise M. Siegel, Craig R. Gibeau
  • Patent number: 5710159
    Abstract: This invention relates to novel heterocycle compounds including but not limited to 3-?3-?3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-pro pionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: January 20, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Matthew Ernst Voss, Prabhakar Kondaji Jadhav, Joanne Marie Smallheer, Douglas Guy Batt, William John Pitts, John Wityak